Research ArticleArticle
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis
William Tillett, Emma Dures, Sarah Hewlett, Philip S. Helliwell, Oliver FitzGerald, Melanie Brooke, Jana James, Jane Lord, Clive Bowen, Martin de Wit, Ana-Maria Orbai and Neil McHugh on behalf of the PROMPT study group
The Journal of Rheumatology August 2017, jrheum.161459; DOI: https://doi.org/10.3899/jrheum.161459
William Tillett
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Emma Dures
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Sarah Hewlett
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Philip S. Helliwell
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Oliver FitzGerald
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Melanie Brooke
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Jana James
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Jane Lord
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Clive Bowen
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Martin de Wit
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Ana-Maria Orbai
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Neil McHugh
From the Royal National Hospital for Rheumatic Diseases; Department of Pharmacy and Pharmacology, University of Bath; PsAZZ Psoriatic Arthritis Support Group, Bath; University of the West of England, Bristol; Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, UK; St. Vincent’s University Hospital and the Conway Institute, University College Dublin (UCD), Dublin, Ireland; Department of Medical Humanities, Patient Research Partner, VU University Medical Centre, Amsterdam, the Netherlands; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. This report is from independent research funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). W. Tillett, MBChB PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath; E. Dures, MSc, PhD, University of the West of England; S. Hewlett, FRCN, PhD, MA, University of the West of England; P.S. Helliwell, MA, MD, LIRMM, University of Leeds; O. FitzGerald, MD, FRCPI, FRCP (UK), St. Vincent’s University Hospital and the Conway Institute, UCD; M. Brooke, Patient Research Partner, Chair, PsAZZ Psoriatic Arthritis Support Group; J. James, Patient Research Partner; J. Lord, Patient Research Partner; C. Bowen, Patient Research Partner; M. de Wit, PhD, Department of Medical Humanities, Patient Research Partner, VU University Medical Centre; A. Orbai, MD, Division of Rheumatology, Johns Hopkins University School of Medicine; N. McHugh, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath. Address correspondence to Dr. W. Tillett, Royal National Hospital for Rheumatic Diseases, Upper Borough Walls, Bath, BA11RL, UK. E-mail: w.tillett@nhs.net. Accepted for publication May 18, 2017.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis
William Tillett, Emma Dures, Sarah Hewlett, Philip S. Helliwell, Oliver FitzGerald, Melanie Brooke, Jana James, Jane Lord, Clive Bowen, Martin de Wit, Ana-Maria Orbai, Neil McHugh
The Journal of Rheumatology Aug 2017, jrheum.161459; DOI: 10.3899/jrheum.161459
A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis
William Tillett, Emma Dures, Sarah Hewlett, Philip S. Helliwell, Oliver FitzGerald, Melanie Brooke, Jana James, Jane Lord, Clive Bowen, Martin de Wit, Ana-Maria Orbai, Neil McHugh
The Journal of Rheumatology Aug 2017, jrheum.161459; DOI: 10.3899/jrheum.161459